As France's leading biocluster, Genopole is an incubator for cutting-edge projects in biotechnology. Located in the city of Évry, just south of Paris, Genopole provides a unique environment for scientists and entrepreneurs seeking to advance research and innovation.

Discover >


Genopole accompanies researchers, postdocs and start-up entrepreneurs through all the phases of their projects to ensure the best possible conditions for business development.

Discover >

Genopole’s citizens

Every day, at Genopole, researchers, entrepreneurs and students cross paths, share ideas and unite forces in a veritable melting pot for innovation.

Discover >


Giving wings to research and empowering employment in our community are cornerstones of Genopole's mission. Catch up on recent scientific advances, the accomplishments of our biotech actors and the events that enliven the biocluster.

Discover >

Innovate with us

Discover >

Santen SAS

1, rue Pierre Fontaine – Building 4
91058 EVRY Cedex – FRANCE
Phone : +33 1 69 87 40 20

Jean-Sébastien GARRIGUE: Research Manager
Web Site >
Santen - Genopole's Company Santen - Genopole's Company

#Health / Well-being #Therapeutics

  • Ophthalmology
  • Technologies
  • Cationorm®

Field of Activity

Santen SAS has developed its own sales force to commercialize ophthalmic products in France while Santen Innovation Center is a center of excellence for Santen Group dedicated to research and development of innovative ophthalmic treatments for all segments of the eye.


For 120 years now, Santen has been continuing its commitment to improving the eyesight and health of patients across the globe, building upon a spirit of creation, innovation and strong company values.

Santen SAS has been marketing the company’s ophthalmological products in France since 2014. The French company is also a Santen Group Center of Excellence dedicated to innovative ophthalmological R&D for all eye segments.


Santen SAS has a sales and marketing organization to commercialize pharmaceutical ophthalmic products in France.

In terms of research activities, within Santen we have concentrated our basic research, non-clinical studies, and drug formulation research at Nara R&D Center, so as to integrate the knowledge of our various sections and create better products. In 2011, Santen purchased Novagali Pharma (today Santen S.A.S.), a French ophthalmic pharmaceutical company that has excellent R&D capability and drug formulation technologies in the dry eye field. This purchase has reinforced Santen’s development pipelines, enhancing its international competitiveness in the ophthalmic field.

  • Further Information

    28 patents
    78 staff members (in France)

    Cationorm®, the first cationic emulsion to treat dry eye symptoms, marketed in more than 50 countries. A portfolio comprising a range of products at various stages of development, particularly the marketed medications Ikervis®, indicated for the treatment of severe keratitis in patients presenting dry eye symptoms, and Verkazia® indicated in severe vernal keratoconjunctivitis in children and adolescents.

    Innovation assets:
    Development of innovative ophthalmological products, patented technologies, bioavailability, tolerability

CompanieGenopole’s Companies

#Health / Well-being

In same field

Vitropep -entreprise genopole


Vitropep developed a unique technology allowing to inject certain peptides without cold chain and with self-administration.

PEP-Therapy - Genopole's Company - logo 2021


PEP-Therapy develops innovative peptides as targeted therapies in oncology. The company operates a unique therapeutic technology based on cell penetrating & interfering peptides (CP&IP). These innovative molecules penetrate cells and specifically block relevant intracellular protein-protein interactions, thus inhibiting key pathological mechanisms.

Exosome Analytics - Entreprise génopolitaine

Exosome Analytics

Exosome Analytics develops techniques for EVs isolation and highly sensitive detection of protein markers on EVs for their application in liquid biopsy.



Platform for the bioproduction of RNA through fermentation in eukaryotic cells, a paradigm shift from in vitro synthesis

Kyron.Bio - Genopole's Company


Kyron.Bio is a biotech company using synthetic biology to produce new therapies with high yield, activity, and stability standards.

CGenetix - Entreprise génopolitaine


CGenetix, is a medTech start-up developing in vitro medical diagnostic devices for the follow-up of transplant patients.

EndoGene.Bio - Genopole's Company


Research & development for an in vitro diagnostic tool for endometriosis

Exosome Analytics - Entreprise génopolitaine

Exosome Analytics

Exosome Analytics develops techniques for EVs isolation and highly sensitive detection of protein markers on EVs for their application in liquid biopsy.

Ciclix - StrokeHub - Genopole's company


Ciclix is a tech driven company specialized in process digitization for hospitals and focused on creating natural and efficient solutions for a variety of user profiles in the hospital environment.

Echoliv -Genopole's company


Echoliv is a MedTech startup that develops solutions based on artificial intelligence and applied to hepatic ultrasound. Our goal is to develop software to assist radiologists and hepatologists.

DeepTope - Genopole's company


– Characterization of antigen / antibody interactions (epitope / paratope) – Optimization of therapeutic antibodies

Theranovir - Genopole's Company


Biotechnology, R&D, Drug development, oncology, obesity, infectious diseases

Cell Environment - Genopole's company

Cell Environment

Cell Environment is a company focusing on DNA damage detection involving unique and repeated sequences such as telomere and centromere sequences.

Innovhem - Entreprise génopolitaine


Our mission is to improve the management of Red Blood Cell diseases and in particular Sickle Cell Disease

Whitelab Genomics - Genopole's Company

WhiteLab Genomics

Artificial intelligence to optimize and accelerate the development of gene therapies

Traaser - Genopole's Company


Software for biomedical data analysis

Synsight - Genopole's Company


Synsight is a company specializing in the discovery and preclinical development of new therapeutic molecules, based on a proprietary, integrated platform, combining artificial intelligence, molecular modeling and a functional experimental screening approach of High-Content Screening (HCS ).

Sebia - Genopole's Company


Design, manufacture and commercialization of in vitro diagnostic systems (instruments and reagents) for medical biology laboratories.

Pharnext - Genopole's company

Pharnext SA

Pharnext develops new therapies and biomarkers based on network pharmacology with a proprietary discovery platform. The company is focused on pathologies with high unmet medical needs. These include neurodegenerative, orphan and common diseases (Charcot-Marie-Tooth disease Type 1A, Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS)).

IntegraGen - Genopole's Company


IntegraGen’s mission is to translate molecular research to clinical practice through the identification of novel genetic biomarkers and the subsequent commercialization of molecular diagnostic tests based on these discoveries.

View all >
With the support from
Région île de France